Buy Dr. Reddy's Laboratories; target of Rs 4900: Prabhudas Lilladher

Trade

• Watchlist
• Portfolio
• Message
• Set Alert

 

 

Choose Stock Exchange: BSE LIVE NSE LIVE

26 Aug, 2025 12:21

Volume

Todays L/H

More

×

Prabhudas Lilladher's research report on Dr. Reddy's Laboratories

Dr. Reddy’s (DRRD) Q3FY23 profitability was sharply ahead of our estimate aided by higher gRevlimid sales. Even base US business grew QoQ. We expect exRevlimid margins to improve with easing of commodity and revenue scaling up with new launches in US. At CMP, DRRD is trading at attractive valuations of 18x P/E on FY25E adjusted for gRevlimid.

Outlook

We maintain our estimates and ‘Buy’ rating with TP of Rs4,900/share. Delay in key ANDA approvals and prolonged inflationary environment of raw material prices are key risks to our call.

For all recommendations report, click here

Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.

Dr. Reddy's Laboratories - 27 -01-2023 - prabhu